Investor’s Watch List: Citigroup (NYSE:C), Cisco Systems (NASDAQ:CSCO), Nokia Corporation (NYSE:NOK), Gilead Sciences, Inc. (NASDAQ:GILD)

Citigroup Inc, (NYSE:C) which has more than 12,000 ATMs worldwide, said it is in the process of upgrading its machines from XP and declined to give further details. Citigroup Inc (NYSE:C) shares after opening at $47.37 moved to $47.82 on last trade day and at the end of the day closed at $46.88. Company price to sales ratio in past twelve months was calculated as 2.25 and price to cash ratio as 0.19. Citigroup Inc (NYSE:C) showed a negative weekly performance of -5.52%.

Cisco Systems, Inc. (NASDAQ:CSCO) is a top name to buy at UBS. The company remains the networking leader and may be forced to really start to show real growth to Wall Street after three straight sub-par earnings reports. While the company has been looking to protect its core business from new competition, stiff competition has started to squeeze the tech giants core earnings power. Cisco Systems, Inc. (NASDAQ:CSCO) shares fell -0.79% in last trading session and ended the day on $21.35. CSCO return on equity ratio is recorded as 14.20% and its return on assets is 8.20%. Cisco Systems, Inc. (NASDAQ:CSCO) yearly performance is 1.91%.

The Supreme Court in India rejected the appeal of Nokia Corporation (ADR) (NYSE:NOK) (BIT:NOK1V) (HEL:NOK1V) to overturn the ruling of a lower court, which required the Finnish company to pay millions of dollars before it can transfer its mobile device factory and other assets in the country to Microsoft Corporation (NASDAQ:MSFT). Nokia Corporation (ADR) (NYSE:NOK) shares moved down -0.26% in last trading session and was closed at $7.54 while trading in range of $7.47 – $7.62 – Nokia Corporation (ADR) (NYSE:NOK) year to date (YTD) performance is -7.03%.

Gilead Sciences Inc. (NASDAQ:GILD) popped 70%, with investors excited about its recently approved oral hepatitis-C treatment, Sovaldi, with its reported cure rates near 90% in clinical trials. Insurers and medical bigwigs are less excited, though, objecting to its very steep price tag of around $84,000 for a 12-week course. Gilead Sciences, Inc. (NASDAQ:GILD) weekly performance is -5.69%. On last trading day company shares ended up $75.05. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is -5.67%. Analysts mean target price for the company is $100.17.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *